Published May 1993 | Version v1
Journal article

[99mTc]teboroxime and [99mTc]Cl(DMG)3B2MP: binding characteristics and metabolism of two [99mTc]BATOs in blood and tissues

  • 1. Bristol-Myers Squibb Pharmaceutical Research Inst., New Brunswick, NJ (United States)

Description

Studies were performed in vitro and in vivo to evaluate the binding properties and metabolism of [99mTc]Cl(CDO)3BMe (Teboroxime) and [99mTc]Cl(DMG)3B2MP in blood and target issues of rats. Both radiopharmaceuticals displayed rapid binding (within 1-3 min) with high affinity to plasma proteins and blood cells. The amounts of radioactivity associated with blood components became progressively greater with time of exposure to either compound. There was a higher proportion of the radiopharmaceuticals associated with blood components during in vivo conditions, likely due, at least in part, to clearance of the free fraction from the plasma pool. Exposure of both compounds to blood results in axial ligand exchange of the chloro atom to a hydroxyl. The results suggest that it is the free species that is extracted primarily by tissues. (Author)

Additional details

Publishing Information

Journal Title
Nuclear Medicine and Biology
Journal Volume
20
Journal Issue
4
Journal Page Range
p. 395-400.
ISSN
0883-2897
CODEN
NMBIEO